Good morning, ladies and gentlemen, and welcome to the Chemed Corporation’s Fourth Quarter 2011 Conference Call. My name is Jennifer, and I’ll be your conference call facilitator today. Please note that today’s call is being recorded. [Operator Instructions] I would now like to turn the call over to Sherri Warner with Chemed Investor Relations. Please proceed.

Good morning. Our conference call this morning will review the financial results for the fourth quarter of 2011 ended December 31, 2011. Before we begin, let me remind you that the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 apply to this conference call. During the course of this call, the Company will make various remarks concerning management’s expectations, predictions, plans and prospects that constitute forward-looking statements. Actual results may differ materially from those projected by these forward-looking statements as a result of a variety of factors, including those identified in the Company's news release of February 14, and in various other filings with the SEC. You are cautioned that any forward-looking statements reflect management’s current view only, and that the Company undertakes no obligation to revise or update such statements in the future. In addition, management may also discuss non-GAAP operating performance results during today’s call, including earnings before interest, taxes, depreciation, and amortization, or EBITDA, and adjusted EBITDA. A reconciliation of these non-GAAP results is provided in the Company’s press release dated February 14, which is available on the Company’s website at chemed.com. I would now like to introduce our speakers for today, Kevin McNamara, President and Chief Executive Officer of Chemed Corporation; Dave Williams, Executive Vice President and Chief Financial Officer of Chemed; and Tim O’Toole, Chief Executive Officer of Chemed’s VITAS Healthcare Corporation Subsidiary. I will now turn the call over to Kevin McNamara.

Thank you, Sherri. Good morning. Welcome to Chemed Corporation’s fourth quarter 2011 conference call. I will begin with some of the highlights for the quarter, and David and Tim will follow with some additional operating detail. I will then open up the call for questions. Chemed consolidated revenue in the quarter totaled $350 million and net income was $25.7 million. If you adjust for certain non-cash items and items that are not indicative of ongoing operations, adjusted net income for the quarter totaled $28.3 million and equated to adjusted earnings per diluted share of $1.45. This is an increase of 19.8% when compared to adjusted earnings per diluted share in the fourth quarter of 2010. During the quarter, our hospice business segment generated revenue of $255 million, an increase of 5.1% over the comparable prior-year period and provided adjusted EBITDA of $40 million. This equated to an adjusted EBITDA margin, prior to Medicare Cap, of 16.6%. Our adjusted EBITDA margin did declined 122 basis points in the fourth quarter of 2011. This is primarily the result of increased costs related to the doctor face-to-face requirement on recertification, and our new start program, which negatively impact our margins an estimated 75 to 100 basis points. In the fourth quarter of 2011, our admissions totaled 15,191, an increase of 2.8% over the prior year quarter. On a full-year basis, admissions have increased 2.8%. Our 2011 admissions growth is attributable to several factors. We expanded our presence in local communities with new or refurbished inpatient units. This provided VITAS with increased visibility to our referral sources, as well as increased capacity to provide hospice care to our high acuity patients. As of December 31, 2011, VITAS has 34 dedicated IPUs with total daily capacity of 458 beds. This is an increase of 7.3%…

Thank you, Kevin. Net revenue for VITAS was $255 million in the fourth quarter of 2011, which is an increase of 5.1% over the prior year period. Excluding the impact of Medicare Cap, revenue actually increased 5.7%. This revenue growth was a result of increased ADC of 4.9%, an increased Medicare reimbursement of 2.5%. ADC growth was driven primarily by an increase at admissions of 2.8% and discharges increasing at a lesser rate of 1.7%. The revenue growth was marginally impacted by a 27 basis point decline in our high acuity care mix, as well as geographic mix shift within the patient base. Average revenue per patient per day in the quarter excluding the impact of Medicare Cap was $203.68, which is 0.7% above the prior year period. Routine homecare reimbursement and high acuity care averaged $161.90 and $707.89, respectively, per patient per day in the fourth quarter of 2011. During the quarter, high acuity days of care was 7.65% of total days of care. Again as I mentioned, 27 basis points lower than the prior year quarter. The fourth quarter of 2011 gross margin excluding the impact of Medicare Cap was 23.8%, which is a decline of 155 basis points from the fourth quarter of 2010. This decline in margin is primarily the result of increased costs related to the 2011 mandated physician visit for recertification, expansion of our community liaison program, expansion of losses in start-up locations, as well as increased costs associated with the expansion of inpatient units. Our homecare direct gross margin was 53.2% in the quarter, a decline of 80 basis points when compared to the fourth quarter of 2010. Direct inpatient margins in the quarter were 13.1%, which compares to a 14.4% in the prior year. Occupancy of our inpatient units averaged 72.5% in…

Thank you, David. We continue to invest significant resources into our marketing and admission focus. One of the most important aspects to increased admissions is appropriately focused field based sales and marketing personnel. As of December 31, 2011, we have 329 sales representatives, 163 admissions coordinators, 359 admission nurses, 109 community liaisons, and 29 long-term care liaisons. Staffing in these areas has expanded 13.5% compared to the fourth quarter of 2010. This focus has resulted in VITAS generating 15,191 admissions in the fourth quarter of 2011, an increase of 2.8% over the prior-year period. Admissions have increased in 3 of our 4 largest referral categories. During the fourth quarter of 2011, home-based admissions increased 7%, assisted-care living facilities increased 2.8%, and hospital referred admissions increased 1.9%. Nursing home admissions declined 2% in the quarter. VITAS's average length of stay in the quarter was 79 days, which compares to 80.8 days in the prior year quarter and 80.1 in the third quarter of 2011. Average length of stay is calculated using total discharges during the quarter. Medium length of stay was 14 days in the quarter. Medium length of stay is a key indicator of our penetration into the high acuity sector of the market. Our days of care totaled 1,262,643 days in the quarter, an increase of 4.9% over the comparable prior year period. Non-nursing home routine homecare days increased to 8.3% in the quarter and nursing home routine home care declined 3.2%. Nursing home days of care currently represents 22.5% of our total days of care. Continuous care days increased 1.2%, and inpatient days of care increased 1.7% when compared to the fourth quarter of 2010. At December 31, 2011, we have 5 programs classified as start-ups. One has passed its CHAP survey, and we’ll be receiving as Medicare license in the first quarter. Two of the new starts are currently billing Medicare and the remaining 2 programs have received the provisional state licenses; have met the patient admission requirement and are awaiting their onsite survey. Total operating losses for these start-ups totaled $1.1 million in the quarter, and compares to losses of $100,000 for locations classified as start-ups in the prior year period. With that, I’ll turn the call back to Kevin.

All right, it’s now the time to consider any questions for the teleconference.

[Operator Instructions] Your first question comes from the line of Brendan Strong from Barclays Capital.

Maybe first, just on the Medicare rate per day only being up 0.7%, I guess that’s a mix issue, could you just give us a little bit more about that?

Yes, it’s exactly a mix issue. So we basically declined 27 basis points in our high acuity, and we average about 160 for routine homecare, but it was, what was it, $700 and change for high acuity. So that has the pretty big impact on the overall average rate.

And as I look at it, it’s interesting because, despite all the investments you guys have made in inpatient, inpatient looks like it’s a lower percentage of revenue in ’11 than it was in ’10. So I mean is that - do you expect that business maybe to grow faster at some point, or is that more just about referral sources really?

Well, remember the inpatient unit when we’re making investment is for increased visibility in the marketplace. It’s not because, all of a sudden there has been a spike in the demand for the high acuity care. It’s increasing basically better real estate, better locations.

All I’d say, there has been no material change, and I wouldn’t expect any, very minor differences you’re speaking about.

Okay, great. And then, just thinking about free cash flow this year, you generated I guess - I don’t know, around $150 million last year, you think you’re looking at a similar amount this year, and then, as a backup plan just to do more share buybacks unless there is some good M&A opportunities you come across?

Well, you have to be careful on the cash flow we generated this year. If you kind of pro form out, for example December 31, 2011, was on a Friday, our fifth payment day. That will exaggerate the cash flow on 2011. In fact, if you look back at 2010, we had the exact opposite occur. So on a raw 12-month basis, the free cash flow look like it was abnormally low. Go back to 2009, it was abnormally high. So you smooth that out, you’re talking about in the low, about $100 million of free cash flow. That’s sustainable, which basically works out to be the free cash flow per share equals our adjusted GAAP EPS. With that said, certainly, acquisitions, but if we don’t like the multiple of acquisitions, dividends and share repurchase will continue.

Your next question comes from the line of Darren Lehrich from Deutsche Bank.

This is Dana Vartabedian in for Darren Lehrich. My first question is on margins, VITAS looked a bit light in the quarter, but Roto-Rooter seems to hold up pretty well. Can you give us a little bit more color on margins, and I guess how we should think about them going forward?

Well, I think we noted in the comments, some investments in the quarter, obviously the face-to-face has required pretty big investment in the new start area in an incremental $1 million, this current period. So all I would say is, I think our margins are stable, and the guidance we provided for next year, I’m comfortable with.

I would just make one additional, as Tim said, there’s some noise in those numbers. The number that is comparative to keep a good handle on is labor, and I would join Tim in saying, I think VITAS has done a great job in managing that number. So if we have labor issues, I’d be concerned with regard to some of the components of the margin calculation, but really I think that we’ve done a great job on the labor control.

And the only thing on the Roto-Rooter margins, they spiked up nicely, but that’s primarily because last year, the fourth quarter of 2010, we had some abnormally high healthcare claims come through. So really we’re seeing Roto-Rooter return more to the norm.

Okay. Okay, great. And then on your 2012 guidance, I guess going back to buybacks, we assume there is no buyback numbers, but you guys seem to be a pretty consistent re-purchasing stock, so I guess how should we think about buyback going into ’12?

There are no, we me make the assumption, no additional buybacks, our share count on a diluted basis is about 19.3 million shares.

Your next question comes from the line of Frank Morgan from RBC Capital Markets.

I wanted to ask a question on the nursing home side, I think, I’ve heard you say that, the number of admissions coming from nursing home sources was down a little bit in the quarter, and I know that particular area had kind of got a lot of heightened attention in some of the MedPAC findings, but is anything you are seeing going on there. I know it’s a smaller part of your business and other players, but any commentary you have on why that’s down, and then kind of how you see the world playing out with nursing home base, hospice down the road?

Well, great. I mean, I think the comment will be similar to what we’ve commented in the past. The total nursing home beds are not growing, and so our performance is mirroring in the industry there. I expect our future performance in the nursing home segment to be good, we work very closely with them, we’re an important partner and hospice is critical to the success of good quality services in the nursing home arena. So I don’t see any changes, and the results are just mirroring the opportunity in the marketplace.

And Frank, one thing I’d add as well, obviously I’ve agreed that 100% seems that, the various government authorities they have, the hospice service in the nursing home environment is under a microscope. There are some things that they don’t like self-referral, they suggest at least the gaming of the system. And there’s questions of a captive hospice market. I mean it doesn’t, we don’t have a significantly higher margin with regard to our nursing home patients, but you can imagine that, it’s hard to pull the numbers, but it’s probably likely been a captive nursing home hospice program would. And I agree with you, that’s going to be something that the whole industry is going to watch pretty closely, because it’s been getting a lot of attention. But again with us, as you’ve started, it’s not a bigger component of our business it is, a lot of the hospice business is - it’s not insignificant, but it’s one that for some time we haven’t put our reliance on as far as we are looking for growth for our company.

Your next question comes from the line of Jim Barrett from CL King & Associates.

Kevin, could you talk about the 2012 in terms of when you listen to what the democrats and the republicans are saying about Medicare and hospice, are you fairly agnostic as to who wins in November, or do you have a preference?

Well, let me put it this way, we're fairly agnostic. I’d say that hospice has support at both sides of aisle. I would say, again this is off the top of my head, I think democrats are a little better for hospice than republicans, but it’s a complicated issue. But it has general support, you have to remember, the biggest rationale for comfort as a provider is that, hospice is a money saver for the federal government and both democrats and republicans are looking to control healthcare spending, and it’s clearly a form of rationing of care, which both sides know that eventually there is going to be rationing of care. It's just that hospice is a voluntary rationing of care. So from a political standpoint, without - I mean, yes, I like my personal income tax rates as well as possible, but obviously for the industry democrats and all that for a hospice generally speaking. But I don’t know whether or so, it really it goes to the heart of one of your question is this, regardless of what the law is sort of reimbursement, hospice will succeed or fail, a hospice company if they control the labor costs. I mean to the extent that, wherever the rate is set, as long as hospice company is fairly nibble and can respond with the right amount of labor within that reimbursement nexus, it will do fine and I think that’s one thing we’re working on internally on a daily basis is to increase our nimbleness in responding on a program by program basis because they’ll be having the right amount of staffing. Right now, with the given reimbursement environment for a census and the extent that reimbursement is going to change or could possibly change, it will just be another part of the calculus. But ultimately, again I don’t want to pinpoint too much other than to say, hospice is a function of having the right amount of labor for the census in the reimbursement environment.

And given your visits per patient or at the high-end of the industry right now, given the pressure on reimbursement. Do you envision ratcheting down those visits per week as we look out 2 to 3 years?

Yes, I’ll put it this way, if they ask me to prognosticate if reimbursement, the sequestration of 2% or if there is a change, if reimbursement continues to not keep pace with inflation within the industry. I think that, we’ve said that the hospice programs that are at the break-even level, they won’t have a choice. They will reduce expenses rather than go out of business. The biggest expense is, as I said is labor, so they’ll reduce labor. If they have the same census and fewer nurses in home healthcare, it will make fewer visits per patient per week. That will happen, and to the extent that, the other, the more efficient hospice companies are now drafting upon their behavior, that may well happen. But the important thing for us is to continue with the level and quality of service that makes referral sources say, I have a number of choices, but the most professional, efficient, reliable hospice company I can refer my patients to is VITAS. So to the extent that all things in life are relative, but to the extent that we always maintain, but call it that advantage in visits per patient per week, I think will be well served.

Okay, it makes sense. And then on a separate subject, you’ve been consistently disciplined and avoiding making acquisitions at high multiples, so for that matter, have you found at the margin or multiples for hospices starting to rationalize at all, and did owe for some of your franchisees who are in employer friendly states?

Yes, I would say this. First of all, with regard to acquisitions, this situation has not gotten better. If you listen to these calls for about a year and a half period, I said, I would be personally surprised if we didn’t make a significant acquisition by the end of the year. The reason that I said that was, there were a number of hospice programs that were for sale, that we were aggressive in our pursuit of them. Our stats from the industry was such that, if there was one for sale they talk to VITAS before they made the final decision. But things have changed a little bit as a result of a couple of acquisitions, the Odyssey pricing, the Beacon hospice pricing, such that it’s just - when compared, we have a pretty high hurdle. We’re buying our own stock, we’re buying hospice when we buy our own stock at about 6 times EBITDA.I mean the questions is, do you want to take a chance, out there in the unknown of buying a hospice at 10 to 12 times EBITDA just in order to build census. And given the fact, if you remember, of all the type of acquisitions that I’ve seen, hospice is fraught with worry, I mean, you don’t get much when you buy a hospice. The patients die by, in short they’re almost by definition; there is no bricks and mortar. And referral source, I’d characterize those relationships are ephemeral. So you don’t get much, and have to accept the idea of paying it princely sum for them to get to a conservative acquirer, it just doesn’t get. So answer to your question is, with regard to hospice, no, I see pricing continue to be high, I don’t see us being real active in that front. On Roto-Rooter side, we’re always very active, the problem is that we’re down to now Roto-Rooter franchisees that have been within the same family stand for 2 generations. And they have a great deal; they pay a very low franchise fee for a great service mark. And again, when they are willing to contemplate the selling, we buy it and before that they’re just really not in the market. But we’re always, we drop anything to make a Roto-rooter acquisition because our experience in our acquisitions has been, it is everyone has been a winner. So having said that, no, I don’t anticipate great growth in 2012 by acquisition. That’s why we’ve expanded our new starts in VITAS, and again, we’ll stick into our meeting in Roto-Rooter and kind of grinded it out.

And there are no further questions at this time. I will now turn the call back over to Kevin McNamara for closing remarks.

Well, I have talked plenty. So I’ll just use this up for you to conclude our fourth quarter 2011 conference call. Thank you.

Ladies and gentlemen, that concludes today’s conference. Thank you for your participation. You may now disconnect. Have a great day.